The present invention is intended to provide a photoresponsive Smo ligand, in which a photodissociable protective group binds to an active site of a Smo ligand (a site important for agonistic or antagonistic activity). Specifically, the present invention relates to a photoresponsive Smo ligand, in which a photodissociable protective group binds to an active site of a Smo ligand. More specifically, it is a photoresponsive Smo ligand, which is characterized in that the Smo ligand is a 1,4-diaminocyclohexane derivative and the photodissociable protective group comprises an aromatic ring.

This disclosure provides particles that are suitable for remotely-triggered therapy for cancer and microbial infection.

There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.

Provided are combinations comprising terbinafine or a pharmaceutically acceptable salt thereof and a NO source. The combination may be a synergistic combination. Also provided are methods of treating and/or preventing a fungal infection in a subject comprising administering terbinafine or a pharmaceutically acceptable salt thereof to the subject; and administering a NO source to the subject, thereby treating and/or preventing the fungal infection in the subject. The dose of terbinafine or a pharmaceutically acceptable salt thereof and the dose of the NO source administered to the subject may achieve a synergistic effect.

A visible light-curable chitosan derivative, a hydrogel thereof, and a preparation method therefor are disclosed. The visible light-curable glycol chitosan derivative is curable by light in the visible light range and has a wound healing activity. A hydrogel obtained by cross-linkage of the visible light-curable glycol chitosan derivative using visible light has a wound healing effect per se, and further, a hydrogel obtained by cross-linkage in a combination of one or more growth factors has an excellent wound healing effect. In addition, a glycol chitosan hydrogel that can prevent the denaturation of contained drugs and growth factors due to the cross-linkage by visible light and is optimized for application to a wet dressing dosage form can be prepared.

A visible light-curable chitosan derivative, a hydrogel thereof, and a preparation method therefor are disclosed. The visible light-curable glycol chitosan derivative is curable by light in the visible light range and has a wound healing activity. A hydrogel obtained by cross-linkage of the visible light-curable glycol chitosan derivative using visible light has a wound healing effect per se, and further, a hydrogel obtained by cross-linkage in a combination of one or more growth factors has an excellent wound healing effect. In addition, a glycol chitosan hydrogel that can prevent the denaturation of contained drugs and growth factors due to the cross-linkage by visible light and is optimized for application to a wet dressing dosage form can be prepared.

The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers. The present invention utilizes in its various aspects, bifunctional compounds or complexes that contain at least two domains. One domain, referred to herein as a targeting moiety, binds an antigen on the surface of a tumor cell. The other domain, referred to herein as a pro-antigen, is designed to be inert to normal (non-diseased) cells and tissues, and to become activated (or unmasked or unaged) only upon exposure to light of an appropriate wavelength.

In one aspect, a chemically-modified siRNA for reversible photo-controlled gene silencing is provided. In one embodiment, one or more nucleotides the sense strand of the siRNA are replaced with a spacer comprising an azobenzene or derivative thereof. The azobenzene or derivative thereof undergoes isomerization between the trans-configuration and the cis-configuration in the presence of light from a light source and the siRNA optionally has higher RNA silencing activity when the azobenzene or derivative thereof is in the trans-configuration compared to the cis-configuration. In other aspects, the chemically-modified siRNAs may, for example, be useful as both therapeutics and research tools.

A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

Compositions and methods are described for delivery of drugs to desired tissues via soluble quantum dots.